Autopsy report · NCT01329549
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
Cause of deathNo reason given
Life of this trial
- Ran for about 1 year 6 months before it stopped.
- 2 participants enrolled.
- Results were posted on the registry 2 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Conditions
- Ovarian Neoplasms
- Interventions
- BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Participants
- 2
- Sites
- 3
- Countries
- Japan
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.